The United States of America as Represented by the Secretary of

Nippon Zeon Company, Ltd.

Other

Keyvan Nazerian

Noboru Yanagida

Richard L Witter

Lucy F Lee

Ping Wu

Aly M Fadly

Shigeto Yoshida

Yi Li

Jay G Calvert

Ryohei Ogawa

A nucleotide sequence encoding the gp82 polypeptide of Marek's disease virus is disclosed. Also disclosed are recombinant viruses which are useful as vaccines for protecting against Marek's Disease, preferably containing two or more genes encoding Marek's Disease Virus antigens such as glycoprotein B and glycoprotein gp82, under the control of a poxvirus promoter within a region of the DNA of fowlpox virus which is not essential for virus growth. Also provided is a vaccine exhibiting a synergistic immunoprotective effect, comprising a recombinant fowlpox virus expressing Marek's Disease Virus gB protein in combination with turkey herpesvirus. A method of immunizing poultry, comprising administering any of the disclosed vaccines, is also provided.

Marek's disease virus vaccines for protection against Marek's disease

A recombinant fowlpox virus is provided which is useful as a vaccine for protection against avian reticuloendo-theliosis virus-associated diseases. In a specific embodiment, the recombinant virus expresses a gene encoding an envelope glycoprotein of spleen necrosis virus under the control of a poxvirus promoter, inserted in a nonessential region of the fowlpox virus genome.

Vaccine comprising fowlpox virus recombinants expressing the envelope

A recombinant fowlpox virus is disclosed which is useful as a vaccine for protection against Marek's Disease. The recombinant virus preferably contains a gene for one or more Marek's Disease Virus antigens such as glycoprotein B homologue, glycoprotein C homologue, glycoprotein D homologue, glycoprotein H homologue and tegument proteins, under the control of a poxvirus promoter within a region of the DNA of fowlpox virus which is not essential for virus growth.

Recombinant fowlpox vaccine for protection against Marek's disease

A lymphoblastoid cell line of turkey origin designated as MDTC-RP-19 and deposited under the ATCC Accession No. CRL-8135 has been found useful for the in vitro propagation of hemorrhagic enteritis virus (HEV). Cocultivation of the apathogenic strain of HEV with the cell line is useful in the production of a vaccine for protecting fowl against virulent HEV.

Propagation of hemorrhagic enteritis virus in a turkey cell line and

Growing community of inventors

Haslett, MI, United States of America

Keyvan Nazerian